{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T22:59:09Z","timestamp":1772233149945,"version":"3.50.1"},"reference-count":35,"publisher":"FapUNIFESP (SciELO)","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Braz. J. Nephrol."],"abstract":"<jats:p>ABSTRACT  Introduction: Rituximab (RTX) is a therapeutic option in pediatric difficult-to-treat idiopathic nephrotic syndrome (NS). We aimed to assess the efficacy and safety of RTX use in these patients.  Method: A retrospective study of all patients with idiopathic NS treated with RTX was conducted in a pediatric nephrology division of a tertiary hospital. Demographic, anthropometric, clinical and analytical data were collected prior to treatment and at 6, 12, and 24 months.  Results: Sixteen patients were included (11 males), with a median (25th\u201375th percentile, P25\u2013P75) age at diagnosis of 2 (2.0\u20132.8) years. Fifteen were steroid-sensitive and 1 was steroid-resistant and sensitive to cyclosporine. The median age at administration of RTX was 10 (6.3\u201314.0) years. Throughout a median follow-up time of 2.5 (1.0\u20133.0) years, 6 (37.5%) patients achieved partial remission and 7 (43.8%) had no relapses and were not taking any immunosuppressants at the 24-month follow-up visit. Regarding complications, 1 patient presented persistent hypogammaglobulinemia. Compared with the 12-month period before RTX, there was a decrease in the median number of relapses at 6 and 12 months [3 (3.0\u20134.0) vs 0 (0\u20130.8) and 0.50 (0\u20131.0), respectively; p = 0.001] and in the daily steroids dose (mg\/kg\/day) at 6, 12, and 24 months [0.29 (0.15\u20130.67)vs [0.10 (0.07\u20130.13); p = 0.001], [0.12 (0.05\u20130.22); p = 0.005] and [0.07(0.04\u20130.18); p = 0.021]], respectively. There was also a reduction in the median BMI z score at 24 months [2.11 (0.45\u20133.70) vs. 2.93 (2.01\u20133.98); p = 0.049].  Conclusion: Our results confirm the efficacy and safety of RTX use in pediatric idiopathic NS and highlight its\u2019 potential cardiometabolic benefits.<\/jats:p>","DOI":"10.1590\/2175-8239-jbn-2022-0056en","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T10:35:49Z","timestamp":1666002949000},"page":"326-334","source":"Crossref","is-referenced-by-count":1,"title":["Rituximab therapy for childhood onset idiopathic nephrotic syndrome: experience of a Portuguese tertiary center"],"prefix":"10.1590","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1246-194X","authenticated-orcid":false,"given":"Rita","family":"Gomes","sequence":"first","affiliation":[{"name":"Centro Hospitalar Universit\u00e1rio do Porto,  Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5474-7236","authenticated-orcid":false,"given":"Sara","family":"Mosca","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Universit\u00e1rio do Porto,  Portugal"}]},{"given":"Mariana","family":"Bastos-Gomes","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade do Alto Minho,  Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-090X","authenticated-orcid":false,"given":"Liane","family":"Correia-Costa","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Universit\u00e1rio do Porto,  Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1393-852X","authenticated-orcid":false,"given":"Liliana","family":"Rocha","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Universit\u00e1rio do Porto,  Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5211-2467","authenticated-orcid":false,"given":"Ana","family":"Teixeira","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Universit\u00e1rio do Porto,  Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6478-4241","authenticated-orcid":false,"given":"Teresa","family":"Costa","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Universit\u00e1rio do Porto,  Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8061-9289","authenticated-orcid":false,"given":"Maria","family":"Sameiro-Faria","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Universit\u00e1rio do Porto,  Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1819-5275","authenticated-orcid":false,"given":"Paula","family":"Matos","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Universit\u00e1rio do Porto,  Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4741-0002","authenticated-orcid":false,"given":"Concei\u00e7\u00e3o","family":"Mota","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Universit\u00e1rio do Porto,  Portugal"}]}],"member":"530","published-online":{"date-parts":[[2023,9]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/17843286.2016.1208955","article-title":"Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature","volume":"72","author":"Van Horebeek I","year":"2017","journal-title":"Acta Clin Belgica Int J Clin Lab Med"},{"issue":"2","key":"ref2","first-page":"83","article-title":"Tratamiento con rituximab en pacientes pedi\u00e1tricos con s\u00edndrome nefr\u00f3tico c\u00f3rtico-dependiente","volume":"96","author":"Morais B","year":"2022","journal-title":"Experiencia en un hospital terciario. Pediatria (Napoli)"},{"issue":"9950","key":"ref3","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"384","author":"Iijima K","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"ref4","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00467-018-4172-3","article-title":"Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome","volume":"34","author":"Maxted AP","year":"2019","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"ref5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","article-title":"Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome a randomized clinical trial","volume":"172","author":"Basu B","year":"2018","journal-title":"JAMA Pediatr"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S2352-4642(18)30283-9","article-title":"Management of steroid-resistant nephrotic syndrome in children and adolescents","volume":"2","author":"Tullus K","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s00467-017-3780-7","article-title":"Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options","volume":"33","author":"Kemper MJ","year":"2018","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13052-016-0271-6","article-title":"The efficacy and safety of rituximab in treating childhood nephrotic syndrome: an Italian perspective","volume":"42","author":"Maratea D","year":"2016","journal-title":"Ital J Pediatr"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00467-018-4166-1","article-title":"Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children","volume":"35","author":"Kamei K","year":"2020","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10157-016-1313-5","article-title":"Rituximab for nephrotic syndrome in children","volume":"21","author":"Iijima K","year":"2017","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00467-021-04983-3","article-title":"Update on the treatment of steroid-sensitive nephrotic syndrome","volume":"37","author":"Zotta F","year":"2022","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"ref12","first-page":"109","article-title":"Single dose of rituximab in children with steroid-dependent\/frequently relapsing nephrotic syndrome, clinical efficacy and evaluation of health-related quality of life","volume":"1","author":"Wang L","year":"2021","journal-title":"Iran J Kidney Dis"},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.kint.2019.09.033","article-title":"Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently-relapsing nephrotic syndrome have important effects on outcomes","volume":"97","author":"Chan EY","year":"2020","journal-title":"Kidney Int"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00467-009-1376-6","article-title":"Rituximab in refractory nephrotic syndrome","volume":"25","author":"Prytu\u0142a A","year":"2010","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00431-017-2891-2","article-title":"ESPN Working Group on Idiopathic Nephrotic Syndrome. Variability of diagnostic criteria and treatment of idiopathic nephrotic syndrome across European countries","volume":"176","author":"Desch\u00ea G","year":"2017","journal-title":"Eur J Pediatr"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1093\/ndt\/gfr548","article-title":"Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome","volume":"27","author":"Kemper MJ","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00467-015-3245-9","article-title":"Cyclophosphamide and rituximab in frequently relapsing\/steroid-dependent nephrotic syndrome","volume":"31","author":"Webb H","year":"2016","journal-title":"Pediatr Nephrol"},{"issue":"9","key":"ref18","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1681\/ASN.2014080799","article-title":"Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial","volume":"26","author":"Ravani P","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"ref19","first-page":"e13157","author":"Ahn YH","year":"2018"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin BH","year":"2021","journal-title":"Kidney Int"},{"issue":"2","key":"ref21","first-page":"70","article-title":"Rituximab use in children with complicated idiopathic nephrotic syndrome \u2013 a single centre experience","volume":"28","author":"Moreira CL","year":"2019","journal-title":"Nascer Crescer"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz GJ","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"46","key":"ref23","doi-asserted-by":"crossref","first-page":"e13157","DOI":"10.1097\/MD.0000000000013157","article-title":"Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea","volume":"97","author":"Ahn YH","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaut.2017.10.006","article-title":"NEPHRUTIX: A randomized, double-blind, placebo vs Rituximab-controlled trial assessing T-cell subset changes in Minimal Change Nephrotic Syndrome","volume":"88","author":"Boumediene A","year":"2018","journal-title":"J Autoimmun"},{"issue":"6","key":"ref25","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1681\/ASN.2021111472","article-title":"Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study","volume":"33","author":"Chan EY","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","article-title":"Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome","volume":"25","author":"Ruggenenti P","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00467-018-4063-7","article-title":"Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study","volume":"34","author":"Takahashi T","year":"2019","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s12882-019-1470-3","article-title":"Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial)","volume":"20","author":"Nagano C","year":"2019","journal-title":"BMC Nephrol"},{"issue":"9","key":"ref29","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.medcli.2020.07.039","article-title":"Efficacy and safety of rituximab for childhood refractory nephrotic syndrome: a meta-analysis of randomized controlled trials","volume":"157","author":"Chang D","year":"2021","journal-title":"Med Clin (Barc)"},{"issue":"4","key":"ref30","article-title":"IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome","volume":"22","author":"Trautmann A","year":"2021","journal-title":"Nephrol Dial"},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1681\/ASN.2011080775","article-title":"Rituximab in children with resistant idiopathic nephrotic syndrome","volume":"23","author":"Magnasco A","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"ref32","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1136\/archdischild-2020-321211","article-title":"Use of rituximab in paediatric nephrology","volume":"106","author":"Sinha R","year":"2021","journal-title":"Arch Dis Child"},{"issue":"10","key":"ref33","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1681\/ASN.2016101121","article-title":"Long-term outcome of steroid-resistant nephrotic syndrome in children","volume":"28","author":"Trautmann A","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/ndt\/gfu267","article-title":"Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome","volume":"30","author":"Sinha A","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"ref35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1136\/archdischild-2019-318019","article-title":"Impact of rituximab on anthropometric indices among childhood steroid-dependent nephrotic syndromes","volume":"106","author":"Sinha R","year":"2021","journal-title":"Arch Dis Child"}],"container-title":["Brazilian Journal of Nephrology"],"original-title":["Terapia com Rituximabe para s\u00edndrome nefr\u00f3tica idiop\u00e1tica de in\u00edcio na inf\u00e2ncia: experi\u00eancia de um centro terci\u00e1rio portugu\u00eas"],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0101-28002023000300326&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T07:20:55Z","timestamp":1697786455000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0101-28002023000300326&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["S0101-28002023000300326"],"URL":"https:\/\/doi.org\/10.1590\/2175-8239-jbn-2022-0056en","relation":{"is-translation-of":[{"id-type":"doi","id":"10.1590\/2175-8239-jbn-2022-0056pt","asserted-by":"subject"},{"id-type":"doi","id":"10.1590\/2175-8239-jbn-2022-0056pt","asserted-by":"object"}]},"ISSN":["2175-8239","0101-2800"],"issn-type":[{"value":"2175-8239","type":"electronic"},{"value":"0101-2800","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}